小6s
Lv12
85 积分
2021-03-03 加入
-
Progress in the controllability technology of PROTAC
3小时前
待确认
-
The present and future of bispecific antibodies for cancer therapy
5小时前
已完结
-
The antibody-drug conjugate landscape
17小时前
已完结
-
The landscape of cancer research and cancer care in China
1天前
已完结
-
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
14天前
已完结
-
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial
14天前
已完结
-
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
14天前
已完结
-
Advancing immunotherapy in small cell lung cancer
26天前
已完结
-
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
30天前
已完结
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
1个月前
已完结